GYRE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
29.1M
+29.2%
22.5M
-39.5%
37.2M
+21.7%
30.6M
+2.8%
29.7M
Cost of Revenue
2.2M
+80.0%
1.2M
-29.6%
1.7M
+7.1%
1.6M
+41.4%
1.2M
Gross Profit
26.9M
+26.3%
21.3M
-39.9%
35.5M
+22.5%
28.9M
+1.2%
28.6M
Operating Expenses
41.3M
+34.6%
30.6M
-13.3%
35.3M
+60.5%
22.0M
-28.6%
30.8M
R&D
19.1M
+184.0%
6.7M
+39.9%
4.8M
+103.8%
2.4M
-71.7%
8.4M
SG&A
21.6M
+1.2%
21.4M
-30.0%
30.5M
+55.3%
19.6M
-12.6%
22.5M
Operating Income
-14363000
-53.5%
-9355000
-7895.8%
120.0K
-98.3%
6.9M
+409.2%
-2240000
EBITDA
-12880000
-48.3%
-8683000
-1165.4%
815.0K
-89.2%
7.6M
+715.4%
-1231000
Net Income
-14270000
-44.8%
-9858000
-621.7%
-1366000
-123.0%
5.9M
+365.4%
-2237000
EPS (Basic)
$-0.12
-20.0%
$-0.10
-400.0%
$-0.02
-150.0%
$0.04
+300.0%
$-0.02
EPS (Diluted)
$-0.12
-20.0%
$-0.10
-900.0%
$-0.01
-133.3%
$0.03
+200.0%
$-0.03
Shares (Diluted)
100.6M
+10.2%
91.3M
-22.3%
117.6M
+13.1%
104.0M
+16.6%
89.2M
Gyre Therapeutics (GYRE) โ€” Financials